Lipid-CTPP Conjugated Nanocarriers for Targeted Drug Delivery in Glioblastoma: In-vitro and in-vivo effects

Rakesh Kumar Sahoo – Research Scholar, Pharmacy, Central University of Rajasthan; Kushagra Nagori – Associate Professor, Department of Pharmaceutical Chemistry, Rungta College of Pharmaceutical Sciences & Research; Ajazuddin ., PhD – Director, Rungta College of Pharmaceutical Sciences & Research; Gajanan Paul – Research Scholar, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, (NIPER) Raebareli; Awesh Yadav – Associate Professor, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, (NIPER) Raebareli; Umesh Gupta, PhD – Associate Professor, Department of Pharmacy, Central University of Rajasthan

Introduction:

Glioblastoma multiforme (GBM) has emerged as a challenge to treat primarily because of its hostile nature and complex pathophysiology. Although, Temozolomide (TMZ) is primary chemotherapeutic agent but its efficacy is limited by poor solubility, restricted BBB permeation, systemic toxicity, and drug resistance. Henceforth, nanomicelles (PMCs) based delivery systems offer a promising approach to overcome these limitations by enhancing mitochondrial targeting, cellular uptake, and therapeutic efficacy of TMZ in brain. In this study, we focused on developing TMZ-loaded nanomicelles (TMZ-TSPC PMCs) for targeted GBM therapy.